GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » PS Ratio

Amicus Therapeutics (Amicus Therapeutics) PS Ratio

: 7.81 (As of Today)
View and export this data going back to 2007. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Amicus Therapeutics's share price is $10.56. Amicus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.35. Hence, Amicus Therapeutics's PS Ratio for today is 7.81.

Good Sign:

Amicus Therapeutics Inc stock PS Ratio (=7.8) is close to 1-year low of 7.8

The historical rank and industry rank for Amicus Therapeutics's PS Ratio or its related term are showing as below:

FOLD' s PS Ratio Range Over the Past 10 Years
Min: 5.47   Med: 24.15   Max: 4540
Current: 7.77

During the past 13 years, Amicus Therapeutics's highest PS Ratio was 4540.00. The lowest was 5.47. And the median was 24.15.

FOLD's PS Ratio is ranked better than
54.41% of 998 companies
in the Biotechnology industry
Industry Median: 9.06 vs FOLD: 7.77

Amicus Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.38. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.35.

During the past 12 months, the average Revenue per Share Growth Rate of Amicus Therapeutics was 18.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 10.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 20.10% per year.

During the past 13 years, Amicus Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 173.60% per year. The lowest was -70.40% per year. And the median was 12.40% per year.

Back to Basics: PS Ratio


Amicus Therapeutics PS Ratio Historical Data

The historical data trend for Amicus Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.85 22.91 10.26 10.72 10.49

Amicus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.72 9.57 10.42 9.55 10.49

Competitive Comparison

For the Biotechnology subindustry, Amicus Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amicus Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's PS Ratio falls into.



Amicus Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Amicus Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=10.56/1.352
=7.81

Amicus Therapeutics's Share Price of today is $10.56.
Amicus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Amicus Therapeutics  (NAS:FOLD) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Amicus Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics (Amicus Therapeutics) Business Description

Traded in Other Exchanges
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Executives
John F Crowley director, officer: Executive Chairman C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark officer: Chief People Officer 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout officer: Principal Accounting Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell director, officer: President and CEO C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg officer: General Counsel & Corp. Secy C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli officer: VP, Program Management 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r. officer: Chief Financial Officer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab director 1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi officer: Chief Financial Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman director 13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do officer: Sr Vice President Discovery C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth officer: Chief Medical Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512